ZURA Zura Bio
- 3.786
- -0.224-5.58%
Zura Bio News
Zura Bio Forms Scientific Advisory Board With Prominent Specialists in Rheumatology, Dermatology, and Immunology
Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio"), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced the formation of a Scientific Advisory Board (SAB) with leading experts from rheumatology, dermatology, and immunology.
Zura Bio Highlights Dual-Pathway Antibody Tibulizumab at Upcoming EULAR 2024 Conference
Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced it will present data
Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) Into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024
Novel, dual-pathway antibody targeting IL-17A and BAFF is expected to enter Phase 2 development in systemic sclerosis in Q4 2024 and hidradenitis suppurativa in Q2 2025 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a
Zura Bio's Latest Market Insights Yet to Be Filed
Zura Bio Announces Participation in June Investor Conferences
Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of senior management will
Zura Bio Files to Sell 41.6M Class A Ordinary Shares for Holders
Zura Bio Ltd applies for sale of securities holders' resale of up to 41.6 million Class A common shares — SEC filing
Zura Bio Ltd applies for sale of securities holders' resale of up to 41.6 million Class A common shares — SEC filing
Express News | Zura Bio Ltd Files for Resale of up to 41.6 Mln Class a Ordinary Shares by the Selling Securityholders - SEC Filing
Zura Bio Insider Bought Shares Worth $496,000, According to a Recent SEC Filing
Arnout Ploos van Amstel, Director, on May 17, 2024, executed a purchase for 80,000 shares in Zura Bio (ZURA) for $496,000. Following the Form 4 filing with the SEC, van Amstel has control over a total
Zura Bio(ZURA.US) Director Buys US$496K in Common Stock
$Zura Bio(ZURA.US)$ Director Ploos van Amstel Arnout purchased 80,000 shares of common stock on May 17, 2024 at an average price of $6.2 for a total value of $496K.Source: Announcement What is stateme
10-Q/A: Quarterly report (Amendment)
Zura Bio Ltd (ZURA) Q1 2024 Earnings: Financial and Strategic Developments
Zura Bio Is Maintained at Outperform by Oppenheimer
Zura Bio Is Maintained at Outperform by Oppenheimer
Oppenheimer: Maintaining the Zura Bio (ZURA.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $16.00 to $21.00.
Oppenheimer: Maintaining the Zura Bio (ZURA.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $16.00 to $21.00.
Oppenheimer Adjusts Zura Bio Price Target to $21 From $16, Maintains Outperform Rating
Zura Bio (ZURA) has an average rating of Buy and price targets ranging from $10 to $26, according to analysts polled by Capital IQ. Price: 4.61, Change: +0.01, Percent Change: +0.11
Zura Bio Q1 2024 GAAP EPS $(0.02) Beats $(0.23) Estimate
Zura Bio (NASDAQ:ZURA) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.23) by 91.3 percent.
10-Q: Quarterly report
Zura Bio Projected Cash Runway Extends Support for Ops Through 2027 >ZURA
Zura Bio Projected Cash Runway Extends Support for Ops Through 2027 >ZURA
Zura Bio 1Q Loss $7.75M >ZURA
Zura Bio 1Q Loss $7.75M >ZURA
Press Release: Zura Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
Zura Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights -- Ended Q1 2024 with $89.8 million in cash and closed oversubscribed $112.5 million private placement i
Analysis
Price Target
No Data
